Using a new approach to enhance immune response in Small Cell Lung Cancer

Who could benefit from this research

What this research studies

This research investigates a novel method to improve the effectiveness of immunotherapy in patients with Small Cell Lung Cancer (SCLC) by targeting a specific protein called DHX9. By inhibiting DHX9, the researchers aim to trigger an immune response that can transform 'cold' tumors into 'hot' tumors, making them more responsive to treatment. The approach involves inducing the production of viral-like nucleic acids within cancer cells, which can stimulate the body's immune system to attack the tumor. Patients may be monitored for changes in tumor behavior and immune response as part of this innovative treatment strategy.

Why it matters

Where this research is happening

• Research Inst of Fox Chase Can Ctr
  Philadelphia, United States Active

Researchers

• Principal investigator: Canadas, Israel — Research Inst of Fox Chase Can Ctr
• Study coordinator: Canadas, Israel

Related research

Other NIH-funded projects on the same topics.

• Targeting DHX9 to boost viral-like immune response in Small Cell Lung Cancer

  A scientist team is testing whether blocking a protein called DHX9 can make aggressive small cell lung cancer more visible to the immune system and more responsive to immunotherapy.

  NIH research Research Inst of Fox Chase Can Ctr · Philadelphia, United States · NIH-11386506

• Blocking DHX9 to wake the immune system against small cell lung cancer

  The team will block a protein called DHX9 in small cell lung cancer to trigger virus-like signals in tumors so they may respond better to immunotherapy.

  NIH research Research Inst of Fox Chase Can Ctr · Philadelphia, United States · NIH-11158849

• Targeting GARP-TGFβ to Improve Immunotherapy in NSCLC

  A new antibody approach aims to block a key TGFβ-related pathway in the tumor environment to help people with non-small cell lung cancer respond better to therapy.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11400422

• Integrated blood and radiomics to guide immunotherapy in metastatic NSCLC

  A research project aims to use blood tests and advanced imaging patterns to personalize first-line immunotherapy choices for people with metastatic non-small cell lung cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11332497

• Blocking a tumor pathway to boost immunotherapy for non-small cell lung cancer

  This project will see if adding a drug that blocks the Hedgehog pathway to immune checkpoint therapy helps people with non-small cell lung cancer by restoring the immune system's CD8 T cells inside tumors.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11319812

• Improving Immunotherapy for Lung Cancer with CT Scans

  This work aims to find new ways to predict which non-small cell lung cancer patients will respond best to immunotherapy using information from their routine CT scans.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11193547

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.